Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) EBITDA (2019 - 2025)

C4 Therapeutics' EBITDA history spans 7 years, with the latest figure at -$20.6 million for Q4 2025.

  • For Q4 2025, EBITDA rose 41.17% year-over-year to -$20.6 million; the TTM value through Dec 2025 reached -$105.0 million, changed 0.08%, while the annual FY2025 figure was -$105.0 million, 0.13% changed from the prior year.
  • EBITDA reached -$20.6 million in Q4 2025 per CCCC's latest filing, up from -$32.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$16.3 million in Q4 2021 to a low of -$35.9 million in Q4 2022.
  • Average EBITDA over 5 years is -$27.7 million, with a median of -$27.3 million recorded in 2022.
  • Peak YoY movement for EBITDA: plummeted 120.62% in 2022, then surged 49.54% in 2024.
  • A 5-year view of EBITDA shows it stood at -$16.3 million in 2021, then crashed by 120.62% to -$35.9 million in 2022, then increased by 5.39% to -$34.0 million in 2023, then fell by 2.94% to -$35.0 million in 2024, then soared by 41.17% to -$20.6 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's EBITDA are -$20.6 million (Q4 2025), -$32.0 million (Q3 2025), and -$26.1 million (Q2 2025).